TLDR
- Immutep shares plummeted approximately 80% following Friday’s announcement that its Phase III lung cancer study was terminated for futility.
- An Independent Data Monitoring Committee advised discontinuing the TACTI-004 trial testing eftilagimod alfa (efti) for first-line NSCLC treatment.
- Baird cut its rating from Outperform to Neutral and reduced its price target dramatically from $7.00 down to $1.00.
- Citizens downgraded IMMP from Market Outperform to Market Perform while eliminating all NSCLC-related revenue estimates.
- Share volume skyrocketed beyond 11 million trades — a massive increase from the typical daily average of approximately 154,000.
Shares of Immutep (IMMP) tumbled approximately 80% during Friday’s trading session following the biotech company’s announcement that it would discontinue its TACTI-004 Phase III clinical trial. The trial had been testing eftilagimod alfa, commonly referred to as “efti,” as a treatment option for patients diagnosed with first-line non-small cell lung cancer (NSCLC).
The termination followed a recommendation from the Independent Data Monitoring Committee (IDMC), which conducted a thorough review of both safety and efficacy metrics. The committee determined that continuing the trial was futile. Put simply: the available data indicated the treatment was unlikely to achieve its primary endpoints even if the study proceeded to completion.
CEO Marc Voigt expressed clear frustration with the findings. “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” Voigt stated in the company’s official announcement.
The company confirmed it will immediately cease enrolling new participants and begin systematically winding down trial operations, which includes completing patient follow-up procedures and closing clinical sites in accordance with regulatory standards.
Wall Street Responds With Downgrades and Target Cuts
The sell-off was immediate — and analysts wasted no time adjusting their positions.
Baird’s Colleen Kusy downgraded IMMP shares from Outperform to Neutral while slashing her price objective from $7.00 to just $1.00. With the stock trading near $2.76 when the downgrade was issued, even that revised target suggested further downside. Baird’s report indicated the firm sees no obvious pathway forward for efti given this outcome.
Citizens’ Reni Benjamin similarly downgraded the stock from Market Outperform to Market Perform. Benjamin also stripped all NSCLC-related revenue projections from his financial model for the company.
Both analysts indicated they expect IMMP shares to trade sideways relative to broader market conditions until the company produces meaningful results from its other randomized clinical studies.
Prior to Friday’s collapse, IMMP stock had been down roughly 3.5% for the year-to-date period, though it had posted gains of 55% over the trailing twelve months. That rally has now been almost entirely wiped out.
The Road Ahead for Immutep
There is one potential bright spot in this otherwise bleak scenario: by ending the TACTI-004 trial, Immutep eliminates the substantial costs associated with running it. Management now anticipates its cash reserves will last significantly longer than the previously projected Q2 2027 timeline. The company plans to provide a revised cash runway forecast once trial closure activities are finalized.
Immutep indicated it will shift focus toward advancing other programs in its development pipeline. That said, given that NSCLC represented the company’s flagship indication, the strategic path ahead appears substantially more constrained.
Friday’s trading activity painted a vivid picture of investor sentiment. More than 11 million shares traded hands during the morning session alone — a staggering figure when compared to the three-month average daily volume of roughly 154,000 shares. That represents approximately 70 times normal trading activity.
The consensus analyst rating for IMMP currently stands at Hold, derived from two Hold ratings. No average price target is available for the stock at present.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
